Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457151 | 0.89 | HPGD (0.39) | SIRT2CYP11B1CYP11B2SMN1; SMN2L3MBTL1 | |
| SCHEMBL9518341 | 0.86 | FLT3 (0.38) | SIRT2 | |
| SCHEMBL9489847 | 0.85 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL4030251 | 0.85 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1483017 | 0.84 | SIRT2 (0.39) | SIRT2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL1735234 | 0.84 | CYP11B1 (0.37) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1040045 | 0.83 | CYP11B1 (0.41) | SIRT2CYP11B1CYP11B2MAPT | |
| SCHEMBL9789313 | 0.83 | SIRT2 (0.42) | SIRT2SMN1; SMN2 | |
| SCHEMBL5682164 | 0.83 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL670904 | 0.83 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
| CN-1054376-C | Substituted 1H-imidazoles | UCB SA (BE) | 2000-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | SIRT2 2925/4885CYP11B1 85/4885CYP11B2 42/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | SIRT2 2925/4885CYP11B1 85/4885CYP11B2 42/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | SIRT2 1929/4885CYP11B1 103/4885CYP11B2 51/4885 |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | SIRT2 2362/4885CYP11B1 9/4885CYP11B2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.